Business
Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio
Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation ABI-H3733 shows favorable pharmacokinetics and safety in Phase 1a study; Phase 1b study expected to begin in 2022 Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported preclinical data from the company’s newly selected core inhibitor candidate, ABI-4334 (4334), and clinical results from the Phase 1a study of ABI-H3733 (3733) in healthy volunteers at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting™. New data from the Phase 2 study of its investigational candidate vebicorvir (VBR) will be highlighted in an oral presentation on Sunday, November 14 at 10 am ET. “Through our core inhibitor research and development pipeline, we continue to generate data that validate core inhibitors as distinct and complementary treatments to standard-of-care nucleo(s)tide (NrtI) therapy in patients with HBV,” said John McHutchison, AO, MD, chief executive officer and president of Assembly Bio. “In order to realize our mission to bring finite and curative treatments to patients with chronic HBV, we must address the key drivers that contribute to HBV’s lifelong persistence in patients. We are encouraged by the data being presented at AASLD, including with our next-generation core inhibitors 3733 and 4334, and we remain confident in our belief that combination strategies centered around core inhibitors and NrtIs will one day contribute to finite, curative therapies and the elimination of HBV.” In the late-breaking poster entitled “Preclinical characterization of ABI-4334, a novel, highly potent core inhibitor for the treatment of chronic hepatitis B virus infection,” preclinical data demonstrate that 4334 inhibits pgRNA encapsidation and cccDNA formation with single-digit nanomolar potency against both these mechanisms of action and is also active across all HBV genotypes. Evaluation in preclinical models predicts tha...